At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 403 enrolled
Drug / intervention
KRP-104 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone.
In Brief
A Phase 2 clinical trial evaluating KRP-104 and Placebo for Type 2 Diabetes. Completed, enrolled 403 participants across 45 sites in 7 countries.
Detailed Summary
The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesArgentina, Czechia, Guatemala, Poland, Russia, South Africa, United States
CollaboratorsKyorin Pharmaceutical Co.,Ltd
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionJan 2011
TodayJul 2026
First PostedOct 15, 2009
Enrollment StartOct 1, 2009
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.7 years ago
Interventions
KRP-104drug
Tablet
Placebodrug
Tablet